CovarsaDx Exhibits IVD Clinical Research Capabilities at ADLM 2026
- CovarsaDx, a CRO specializing in in vitro diagnostics and medical devices, will exhibit at ADLM Annual Scientific Meeting July 26–30 in Anaheim.
- The company showcases end-to-end IVD clinical research services including regulatory strategy, protocol design, site management, and submission-ready reporting for 510(k), De Novo, and PMA pathways.
- CovarsaDx appointed Lisa Baumhardt as Senior Director of Regulatory Affairs, bringing 30+ years of medical device and IVD regulatory experience from FDA law and industry roles.
Operational Impact
CovarsaDx's addition of a senior regulatory strategist with FDA pre-submission and De Novo/PMA experience strengthens its competitive positioning for sponsors seeking integrated regulatory and clinical execution in the IVD space.
Source: PR Newswire pharma category RSS